Media registration
ESMO welcomes media interested in obtaining information and reporting on cancer issues. Registration is free to bona fide journalists on presentation of a letter of assignment and a valid press card. Media representatives are required to observe and abide by the ESMO Media Policy which applies to all ESMO events.
Accredited journalists will have access to the ESMO official press conferences (as per timeline below), all congress sessions, the e-poster area, the virtual exhibition area, industry satellite symposia, and the congress webcasts.
The media accreditation process is closed, please refer to the ESMO Press Office (media@esmo.org) for any question.
ESMO Press Programme
The following abstracts are currently included in the ESMO Press Programme and will be accompanied by a press release. The ESMO Press Programme is still under finalisation, and therefore changes may apply to this table.
Please note that for some of them, the publication schedule may differ from the general one posted below.
Upon publication, direct link to the press releases will be added.
FPN |
Title |
Author Name |
Abstract Embargo Lift |
Press Release Distribution |
|---|---|---|---|---|
LBA70_PR |
The Impact of COVID-19 on Oncology Professionals: Initial Results of The ESMO Resilience Task Force Survey Collaboration |
Banerjee |
Monday, 14 September 2020 at 00:05 CEST |
Monday, 14 September 2020 at 00:05 CEST |
LBA76_PR |
Expected medium and long term impact of the COVID-19 outbreak in Oncology |
Jerusalem |
||
1581O_PR |
Estimation of European cancer burden for the year 2020 |
Dyba |
||
1613P_PR |
An estimate of the 2-year oncology workload generated by each new patient: a real world study |
Garattini |
||
1678P_PR |
The Impact of COVID-19 Pandemic on Cancer Care: A Global Collaborative Study |
Jazieh |
||
LBA66_PR |
Disparities in access to oncology clinical trials in Europe in the period 2009-2019 |
Carneiro |
Friday, 18 September 2020 at 00:05 CEST |
Friday, 18 September 2020 at 00:05 CEST |
1588MO_PR |
A comparative study on costs of cancer and access to medicines in Europe |
Wilking |
||
696O_PR |
Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: first results from the randomized phase 3 CheckMate 9ER trial |
Choueiri |
Saturday, 19 September 2020 at 00:05 CEST |
Saturday, 19 September 2020 at 18:30 CEST |
LBA3_PR |
An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement. Primary end-point analysis of Lung ART (IFCT-0503, UK NCRI, SAKK) NCT00410683 |
Le Pechoux |
Saturday, 19 September 2020 at 00:05 CEST |
Sunday, 20 September 2020 at 18:30 CEST |
LBA5_PR |
Abemaciclib in high risk early breast cancer |
Johnston |
Saturday, 19 September 2020 at 00:05 CEST |
Sunday, 20 September 2020 at 18:30 CEST |
LBA6_PR |
Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the checkmate 649 study |
Moehler |
Saturday, 19 September 2020 at 00:05 CEST |
Monday, 21 September 2020 at 18:30 CEST |
LBA7_PR |
Nivolumab with chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric or gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study |
Boku |
||
LBA8_PR |
Pembrolizumab Plus Chemotherapy Versus Chemotherapy as First-Line Therapy in Patients With Advanced Esophageal Cancer: The Phase 3 KEYNOTE-590 Study |
Kato |
Third-party media activities
Media activities initiated by third parties during or in connection with the event are subject to the ESMO Policy on Third-Party Media Activities which aims to guarantee proper and correct distribution of oncology and cancer-related information to media representatives in connection with the event. Such media activities include (but are not limited to):
- Meetings such as press conferences, media briefings and educational sessions involving media representatives
- PR activities, such as press releases, news, articles, interviews, etc.
Press events concomitant with/or during breaks of the scientific programme of the event are subject to ESMO Press Office approval.
Please submit your request by contacting the ESMO Press Office at media@esmo.org.
Blackout times
During Blackout times any media activity initiated by third parties is not allowed.
Saturday 19 September 2020 from 11:00 to 20:00 CEST
Sunday 20 September 2020 from 12:30 to 20:00 CEST
Monday 21 September 2020 from 12:30 to 20:00 CEST
Friday 16 October 2020 from 10:30 to 17:30 CEST
Saturday 17 October 2020 from 10:30 to 17:30 CEST
Sunday 18 October 2020 from 10:30 to 17:30 CEST
All third parties wishing to hold media events are kindly requested to adhere to the specific media policy and be in contact through media@esmo.org.
Publication schedule for accepted abstracts
Data and information included in accepted abstracts is under embargo until the relevant embargo release date cited in the schedule below.
Data and information beyond what is included in all accepted abstracts, including full data sets and full manuscripts, may only be made public at the start of the official programme session during which the study is presented.
Abstracts |
Date and time |
|---|---|
|
Abstracts accepted as:
|
Monday, 14 September 2020 |
|
Abstracts and late-breaking abstracts accepted as:
|
Friday, 18 September 2020 |
|
Abstracts and late-breaking abstracts accepted as:
|
Saturday, 19 September 2020 |
Abstracts and late-breaking abstracts selected for inclusion in the ESMO Press Programme (suffix ‘PR’) |
Published according to a dedicated schedule to be made available by early September. |
Contact
ESMO Press Office
E-mail: media@esmo.org
Press release distribution